Sagimet Biosciences Inc’s filing revealed that its President & CEO Happel David unloaded Company’s shares for reported $0.6 million on Jul 21 ’25. In the deal valued at $9.13 per share,65,478 shares were sold. As a result of this transaction, Happel David now holds 689,722 shares worth roughly $6.04 million.
Then, Martins Eduardo Bruno sold 8,277 shares, generating $75,607 in total proceeds. Upon selling the shares at $9.13, the Chief Medical Officer now owns 106,936 shares.
Before that, Rozek Elizabeth sold 10,780 shares. Sagimet Biosciences Inc shares valued at $98,471 were divested by the General Counsel and CCO at a price of $9.13 per share. As a result of the transaction, Rozek Elizabeth now holds 183,726 shares, worth roughly $1.61 million.
Wedbush initiated its Sagimet Biosciences Inc [SGMT] rating to an Outperform in a research note published on August 11, 2025; the price target was $28. Canaccord Genuity began covering SGMT with “Buy” recommendation on July 24, 2025. Oppenheimer started covering the stock on December 06, 2024. It rated SGMT as “an Outperform”.
Price Performance Review of SGMT
On Monday, Sagimet Biosciences Inc [NASDAQ:SGMT] saw its stock jump 0.23% to $8.75. Over the last five days, the stock has gained 3.55%. Sagimet Biosciences Inc shares have risen nearly 232.70% since the year began. Nevertheless, the stocks have risen 94.44% over the past one year. While a 52-week high of $11.41 was reached on 07/25/25, a 52-week low of $1.73 was recorded on 04/07/25.
Levels Of Support And Resistance For SGMT Stock
The 24-hour chart illustrates a support level at 8.51, which if violated will result in even more drops to 8.28. On the upside, there is a resistance level at 9.10. A further resistance level may holdings at 9.44.
How much short interest is there in Sagimet Biosciences Inc?
A steep rise in short interest was recorded in Sagimet Biosciences Inc stocks on 2025-07-15, dropping by -0.43 million shares to a total of 3.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 3.81 million shares. There was a decline of -12.66%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 12, 2024 when UBS began covering the stock and recommended ‘”a Buy”‘ rating along with a $12 price target.
